Faron Pharma Share News (FARN)
FARN Share
FARN Share
FARN Share
FARN Share
FARN
FARN Share
FARN Level 2
FARN Live
FARN Broker
FARN Directors
FARN Financial
FARN
FARN Short
FARN
Last checked at -
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Friday said it has made several managerial changes, which it believes will strengthen its operating performance.The clinical stage said
Read more
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals updated the market on its board and management team on Friday, announcing that Yrjö Wichmann was leaving his current role as its chief financial officer to take up the new position of vice-president, financing and investor relations.
Read moreLONDON (Alliance News) - Biopharmaceutical company Faron Pharmaceuticals Ltd said Tuesday that it has raised EUR1.3 million via share subscription.The company has issued 1.8 million shares
Read moreLONDON (Alliance News) - Faron Pharmaceuticals Ltd on Tuesday reported a slightly narrowed annual loss as the drug developer's research & development costs fell.Faron is a clinical
Read moreLONDON (Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it is unable to explain the recent movement in its share price.Faron noted Thursday's 43% share price rise, and said
Read moreWednesday 1 May J SainsburyFull Year ResultsConnect GroupHalf Year GroupQ1 Stock
Read moreLONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said its Japanese licensing partner Maruishi Pharmaceutical Co Ltd has provided clinical trial results on its phase three Traumakine for
Read moreLONDON (Alliance News) - Faron Pharmaceuticals Oy is to target colorectal cancer in its upcoming test programme for Clevegen, it said Thursday.The testing of Clevegen on patients with will
Read more(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Thursday that the cohort expansion part of its phase 1 and 2 'MATINS' clinical trial, investigating the safety and efficacy of its wholly-owned novel precision cancer immunotherapy 'Clevegen', would begin with patients suffering from late-stage colorectal cancer as soon as the optimal dosing was determined.
Read moreLONDON (Alliance News) - Finland's Faron Pharmaceuticals Oy on Tuesday afternoon said it has raised EUR3.1 million pursuant to a placing announced earlier in the day.The company issued
Read moreLONDON (Alliance News) - Finland's Faron Pharmaceuticals Oy on Tuesday said it expects further disappointing results from Traumakine, as it plans a share placing.Faron is currently for
Read moreLONDON (Alliance News) - Faron Pharmaceuticals Ltd on Thursday said early results from a trial of its Clevegen cancer drug are encouraging.Shares in Faron were up 10% at 64.00 pence on said
Read more(Sharecast News) - Shares in Faron Pharmaceuticals were surging on Thursday morning, after it announced an update on early observations on immunity and clinical response of MATINS patients after administration of its 'Clevegen' product.
Read moreLONDON (Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said new data supports the use of Clever-1 antibodies in re-activating an immune response to tumours.Shares in Faron were up
Read more(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals issued interim results from its pharmacokinetic/dynamic 'YODA' study on Wednesday, examining various formulations of recombinant human interferon-beta (IFN-beta).
Read more
Last checked at